High Throughput 3D Cell Assay for Metastatic Prostate Cancer

Information

  • Research Project
  • 8652646
  • ApplicationId
    8652646
  • Core Project Number
    R41CA165463
  • Full Project Number
    3R41CA165463-01A1S1
  • Serial Number
    165463
  • FOA Number
    PA-12-100
  • Sub Project Id
  • Project Start Date
    7/1/2013 - 11 years ago
  • Project End Date
    11/30/2013 - 10 years ago
  • Program Officer Name
    EVANS, GREGORY
  • Budget Start Date
    7/1/2013 - 11 years ago
  • Budget End Date
    11/30/2013 - 10 years ago
  • Fiscal Year
    2013
  • Support Year
    01
  • Suffix
    A1S1
  • Award Notice Date
    8/31/2013 - 10 years ago
Organizations

High Throughput 3D Cell Assay for Metastatic Prostate Cancer

DESCRIPTION (provided by applicant): Prostate cancer is the most common non-skin cancer in United States men. Despite recent advances, prostate cancer mortality still remains high due to the emergence of therapy-resistant cancer cells that metastasize. This lack of effective therapies against metastatic cancer exists, at least in part, because of lack of drug screening platforms that address the unique nature of metastastatic prostate cancer cells and their microenvironment. Recently, our collaborators have found that prostate cancer (PCa) cells act as molecular parasites as they metastasize to bone and harvest resources from the hematopoietic stem cell (HSC) niche environment where they stay dormant and resistant to conventional anti-cancer drugs. If the dormant metastasized PCa cells that parasitize the HSC niche could be recreated in vitro, they would serve as ideal platforms to screen specifically for anti-metastatic PCa drugs. We have recently shown that 3D co-culture spheroids can mimic the PCa cell parasitized HSC niche thereby maintaining PCa cells in a physiological, more quiescent state. What is required to take advantage of the metastatic PCa microtissue engineering capability we have acquired for drug screening applications is to develop a high throughput format of these types of co-culture spheroids. Towards this end, this Phase I STTR proposal will: Aim 1: Validate a 384 array hanging drop plate system for preparation of the co-culture spheroids. This is a major focus of 3-D Biomatrix, LLC. We have already modified our published platform (Tung et al. 2011) to: enhance droplet stability, facilitate pipette tip insertin, mitigate evaporation, and preserve sterility during optical analysis (Figure 1A). We will perform high throughput performance validations for fluorescence, transmitted light, and bioluminescence assays (Z'- factor), and further refine the design as necessary. Aim 2: Create arrays of microengineered 3D tissues of bone metastasized PCa in the quiescent state. This will be the focus of the Takayama lab at the University of Michigan. To develop procedures to utilize the 384 array hanging drop plate to form co-culture spheroids of PCa cells, marrow stromal cells (MSCs), and human bone marrow endothelial cells (HBMECs) similar to those prepared previously in low throughput microfluidic devices. We will also confirm quiescence of the PCa cells in these co-culture spheroids. The biological hypothesis that motivates this study is: We can treat metastatic PCa better by developing drugs that specifically target dormant metastatic PCa cells that are parasitizing the HSC niche. PHS 398 (Rev. 11/07) Page 1

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R41
  • Administering IC
    CA
  • Application Type
    3
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    34628
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:34628\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
  • Study Section Name
  • Organization Name
    3D BIOMATRIX, INC.
  • Organization Department
  • Organization DUNS
    961839573
  • Organization City
    Ann Arbor
  • Organization State
    MI
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    481095001
  • Organization District
    UNITED STATES